Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:662  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 
 
CASE REPORT
Year : 2020  |  Volume : 12  |  Issue : 4  |  Page : 221-224

Colchicine, aspirin, and montelukast – A case of successful combined pharmacotherapy for adult multisystem inflammatory syndrome in COVID-19


1 Department of Medicine, Sarasota Memorial Hospital, Sarasota, Florida, USA
2 Department of Medicine, IGMC, Shimla, Himachal Pradesh, India
3 Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA
4 Department of Emergency Medicine, Sarasota Memorial Hospital, Sarasota, Florida, USA
5 Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
6 Department of Research and Innovation, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA

Correspondence Address:
Dr. Vivek Chauhan
Department of Medicine, IGMC, Shimla, Himachal Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jgid.jgid_296_20

Rights and Permissions

Since the beginning of the COVID-19 pandemic, many therapeutic strategies have been tried, with mixed results, to prevent and treat adult multisystem inflammatory syndrome in COVID-19 (AMIS-COVID-19). The reason behind this may the complex web of highly intertwined pathophysiologic mechanisms involved in the SARS-CoV-2 infection and the corresponding human systemic response, leading to end-organ damage, disability, and death. Colchicine, high-dose aspirin, and montelukast are being investigated currently as potential modulators of AMIS-COVID-19 in patients who fail to improve with traditional therapeutic approaches. Here, we present a patient who presented with high fevers, extreme fatigue and dyspnea, and ongoing deterioration. As part of our clinical approach, we used the simultaneous combination of the three agents listed above, capitalizing on their different respective mechanisms of action against AMIS-COVID-19. Following the initiation of therapy, the patient showed symptomatic improvement within 24 h, with the ability to return to daily activities after 72 h of continued triple-agent approach. Based on this experience, we have reviewed the immunomodulatory basis of this regimen, including potential avenues in which it may prevent the development of cytokine release syndrome (CRS) and its clinical manifestation, AMIS-COVID-19. By blocking the early stages of an inflammatory response, via diverse mechanistic pathways, the regimen in question may prove effective in halting the escalation of CRS and AMIS-COVID-19 in acutely symptomatic, nonimproving COVID-19 patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed880    
    Printed38    
    Emailed0    
    PDF Downloaded10    
    Comments [Add]    

Recommend this journal

 

Sitemap | What's New | Feedback | Copyright and Disclaimer | Contact Us
2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008